Amniotic Fluid Biomarkers for Symptomatic Fetal CMV Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing congenital cytomegalovirus (CMV) infection in fetuses are inadequate, particularly in distinguishing between symptomatic and asymptomatic infections, and lack reliable prenatal biomarkers for timely medical intervention.
Innovation Solution
The use of specific biomarkers, including proteins such as RARRES2 and LGALS3BP, to determine the presence and severity of CMV infection in amniotic fluid, allowing differentiation between symptomatic and asymptomatic fetuses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amniocentesis with CMV qPCR testing in amniotic fluid is performed, then fetal infection is reliably identified, but the ability to distinguish between symptomatic and asymmetric infections is lost
Solution Approach 1:
The diagnostic approach is segmented into two independent measurement components: (1) CMV viral load detection to identify infection presence, and (2) biomarker panel analysis (including RARRES2, LGALS3BP, and other proteins) to characterize disease severity. This segmentation allows each component to serve its specific function without compromising the other, resolving the contradiction between reliable infection identification and disease severity differentiation.
Solution Approach 2:
A panel of biomarkers acts as an intermediary between the CMV infection and the clinical phenotype. These biomarkers (RARRES2, LGALS3BP, and others) are not directly caused by CMV but serve as mediators that reflect the infection's impact on fetal tissues, enabling indirect assessment of disease severity while maintaining direct detection of viral presence through qPCR.
2Loss of information
If fetal blood sampling by cordocentesis is performed to obtain fetal blood parameters, then prognostic information is obtained, but fetal loss risk increases
Solution Approach 1:
Amniotic fluid serves as an intermediary medium that safely provides access to fetal biomarkers without requiring invasive cordocentesis. The biomarkers (RARRES2, LGALS3BP, and others) are detected in the amniotic fluid, which can be obtained through routine amniocentesis, thereby providing prognostic information while avoiding the 1-3% fetal loss risk associated with cordocentesis.
Solution Approach 2:
Instead of directly sampling fetal blood, the method uses amniotic fluid as a copy or surrogate medium that contains fetal-derived biomarkers. This copying approach allows indirect measurement of fetal status through proteins secreted into the amniotic environment, eliminating the need for direct invasive fetal blood sampling while preserving diagnostic accuracy.
3Productivity
If prenatal treatment with valacyclovir is administered, then promising results are achieved in fetuses with non-severe ultrasound symptoms, but the ability to identify suitable candidates is compromised
Solution Approach 1:
The biomarker panel (RARRES2, LGALS3BP, and others) is measured in advance through amniocentesis to stratify fetuses into different risk categories before treatment decision-making. This preliminary characterization allows clinicians to identify which fetuses with non-severe ultrasound findings are most likely to benefit from valacyclovir treatment, transforming the treatment approach from blind administration to targeted intervention based on objective biomarker data.
Data Source
AI summary
The present invention provides biomarkers allowing the diagnosis of symptomatic congenital cytomegalovirus (CMV) infection and in particular to differentiate between symptomatic and asymptomatic infected fetuses, methods of diagnosis of CMV using said biomarkers, diagnostic kits comprising thereof, and use of the kits and methods of diagnosing fetuses infected with a symptomatic congenital cytomegalovirus (CMV).